|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|||
|
a)
|
Name
|
Mr D E
Troy
|
||
|
b)
|
Position/status
|
SVP
& General Counsel
|
||
|
c)
|
Initial
notification/ amendment
|
Initial
notification
|
||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|||
|
a)
|
Name
|
GlaxoSmithKline
plc
|
||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|||
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W1053
|
||
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2018 on ADSs held in the Company's US
Deferred Performance Share Plan.
|
||
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
|
$36.84
|
437.191
|
|||
|
$36.84
|
6.738
|
|||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
443.929
$36.84
|
||
|
e)
|
Date of
the transaction
|
2018-01-11
|
||
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
||
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: January
15, 2018
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|